Provectus Pharmatech, Inc

Pfizer Corporation

Uti Limited Partnership

Provectus Pharmaceuticals, Inc.

The Rockefeller University

H. Lee Moffitt Cancer Center and Research Institute, Inc.

University of Calgary

Jamie Singer

Eric A Wachter

H Craig Dees

Craig J Eagle

Timothy C Scott

Marlon Lutz

Aru Narendran

Satbir Thakur

Lucy Swift

Chunfen Zhang

Kevin Babiak

Mohit Jain

Sahadeva Reddy Damireddi

Shari Pilon-Thomas

Amod A Sarnaik

Hao Liu

J Robert Durrwachter

James G Krueger

Sandra Garcet

Shari Philon-Thomas

Tanya Trippett

Amod Sarnaik

A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.

In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and/or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-&#x3b1;, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors. Treatment of other epithelial tissue, such as the lining of the gut, is also disclosed.

Combination of local and systemic therapies for enhanced treatment of dermatologic conditions

A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.

Combination of local rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

A cancer immunotherapy method is disclosed in which 'induced immune anticancer agents' are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.

Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound

Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

Combination of local and systemic immunomodulative therapies for melanoma and liver cancer

A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100&#xb0; C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments.

Process for the synthesis of 4,5,6,7-tetrachloro-3',6&#x2032;-dihydroxy-2&#x2032;,4&#x2032;,5&#x2032;,7&#x2032;-tetraiodo-3H-spiro[isobenzofuran-1,9&#x2032;-xanthen]-3-one(Rose Bengal) and related xanthenes

Process for the synthesis of 4,5,6,7-tetrachloro-3',6&#x2032;-dihydroxy-2&#x2032;, 4&#x2032;, 5&#x2032;7&#x2032;-tetraiodo-3H-spiro[isobenzofuran-1,9&#x2032;-xanthen]-3-one (Rose Bengal) and related xanthenes

Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

Process for the synthesis of 4,5,6,7-tetrachloro-3',6&#x2032;-dihydroxy-2&#x2032;,4&#x2032;,5&#x2032;,7&#x2032;-tetraiodo-3H-spiro[isobenzofuran-1,9&#x2032;-xanthen]-3-one (rose bengal) and related xanthenes

Growing community of inventors

Knoxville, TN, United States of America

Jamie Singer